These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 13950710)

  • 1. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine.
    GROOT H; RIBERIRO RB
    Bull World Health Organ; 1962; 27(6):699-707. PubMed ID: 13950710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological reactions in Rhesus monkeys inoculated with the 17D strain of yellow fever virus.
    GROOT H
    Bull World Health Organ; 1962; 27(6):709-15. PubMed ID: 13950709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine.
    ROSENZWEIG EC; BABIONE RW; WISSEMAN CL
    Am J Trop Med Hyg; 1963 Mar; 12():230-5. PubMed ID: 13975014
    [No Abstract]   [Full Text] [Related]  

  • 4. YELLOW FEVER VACCINATION IN MALAYA BY SUBCUTANEOUS INJECTION AND MULTIPLE PUNCTURE. HAEMAGGLUTININ-INHIBITING ANTIBODY RESPONSES IN PERSONS WITH AND WITHOUT PRE-EXISTING ANTIBODY.
    SMITH CE; MCMAHON DA; TURNER LH
    Bull World Health Organ; 1963; 29(1):75-80. PubMed ID: 14043754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria.
    Omilabu SA; Adejumo JO; Olaleye OD; Fagbami AH; Baba SS
    Comp Immunol Microbiol Infect Dis; 1990; 13(2):95-100. PubMed ID: 2208973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.
    Monath TP; Craven RB; Muth DJ; Trautt CJ; Calisher CH; Fitzgerald SA
    Am J Trop Med Hyg; 1980 Jul; 29(4):624-34. PubMed ID: 7406113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever vaccination in Malaya by subcutaneous injection and multiple puncture. Neutralizing antibody responses in persons with and without pre-existing antibody to related viruses.
    SMITH CE; TURNER LH; ARMITAGE P
    Bull World Health Organ; 1962; 27(6):717-27. PubMed ID: 13993152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA.
    Niedrig M; Lademann M; Emmerich P; Lafrenz M
    Trop Med Int Health; 1999 Dec; 4(12):867-71. PubMed ID: 10632996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological studies with group B arthropod-borne viruses. VI. Hemagglutination-inhibiting antibody responses to 17D yellow fever vaccine in human subjects with different degrees of complexity of pre-vaccination group B virus experience.
    Hatgi JN; Wisseman CL; Rosenzweig EC; Harrington BR; Kitaoka M
    Am J Trop Med Hyg; 1966 Jul; 15(4):601-10. PubMed ID: 5941178
    [No Abstract]   [Full Text] [Related]  

  • 10. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.
    Poland JD; Calisher CH; Monath TP; Downs WG; Murphy K
    Bull World Health Organ; 1981; 59(6):895-900. PubMed ID: 6978196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
    Reinhardt B; Jaspert R; Niedrig M; Kostner C; L'age-Stehr J
    J Med Virol; 1998 Oct; 56(2):159-67. PubMed ID: 9746073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibody responses in Japanese volunteers after immunization with yellow fever vaccine].
    Taga K; Imura S; Hayashi A; Kamakura K; Hashimoto S; Takasaki T; Kurane I; Uchida Y
    Kansenshogaku Zasshi; 2002 Sep; 76(9):738-46. PubMed ID: 12391677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1987 yellow fever epidemics in Oyo State, Nigeria: a survey for yellow fever virus haemagglutination inhibiting antibody in residents of two communities before and after the epidemics.
    Olaleye OD; Omilabu SA; Faseru O; Fagbami AH
    Virologie; 1988; 39(4):261-6. PubMed ID: 2851207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination.
    Vázquez S; Valdés O; Pupo M; Delgado I; Alvarez M; Pelegrino JL; Guzmán MG
    J Virol Methods; 2003 Jun; 110(2):179-84. PubMed ID: 12798246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The inhibiting effect of anticholera vaccination carried out simultaneously or at short intervals on yellow fever immunization. Is it real or assumed? Results of a retrospective study].
    Poveda JD; Raccurt CP; Le Fur R; M'Bailara L; Malvy JM; Le Bras M; Saliou P; Fleury HJ
    Bull Soc Pathol Exot; 1990; 83(4):529-35; discussion 535-6. PubMed ID: 2286006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative clinical study of a new 17D thermostable yellow fever vaccine.
    Roche JC; Jouan A; Brisou B; Rodhain R; Fritzell B; Hannoun C
    Vaccine; 1986 Sep; 4(3):163-5. PubMed ID: 3532602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serologic survey for yellow fever and other arboviruses among inhabitants of Rio Branco, Brazil, before and three months after receiving the yellow fever 17D vaccine].
    Tavares-Neto J; Freitas-Carvalho J; Nunes MR; Rocha G; Rodrigues SG; Damasceno E; Darub R; Viana S; Vasconcelos PF
    Rev Soc Bras Med Trop; 2004; 37(1):1-6. PubMed ID: 15042172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RESPONSE OF VOLTA CHILDREN TO JET INOCULATION OF COMBINED LIVE MEASLES, SMALLPOX AND YELLOW FEVER VACCINES.
    MEYER HM; HOSTETLER DD; BERNHEIN BC; ROGERS NG; LAMBIN P; CHASSARY A; LABUSQUIERE R; SMADEL JE
    Bull World Health Organ; 1964; 30(6):783-94. PubMed ID: 14215185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies.
    Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Costa-Pereira C; Yamamura AY; Lima SMB; Simões M; Campos FMF; de Castro Zacche Tonini A; Lemos EM; Brum RC; de Noronha TG; Freire MS; Maia MLS; Camacho LAB; Rios M; Chancey C; Romano A; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA;
    J Immunol Methods; 2017 Sep; 448():9-20. PubMed ID: 28514646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.